Medicinal Chemistry & Drug Development
Medicinal chemistry plays a crucial role in the development of novel psychedelic compounds, focusing on their molecular structures and interactions. Researchers utilise innovative methods to enhance safety and efficacy in psychedelic substances.
Key Insights
- 1
Research indicates that molecular modifications can enhance the therapeutic potential of psychedelics, balancing efficacy with safety.
- 2
Institutes are increasingly employing AI technologies to streamline the discovery of new psychedelic compounds, revealing complex data patterns.
- 3
Novel compounds like 5-MeO-DMT and the 2C-series show promise in both clinical and therapeutic settings, deserving more research attention.
- 4
Increased understanding of neurochemistry through medicinal chemistry is leading to breakthroughs in reconstructing traditional psychedelics for modern treatment paradigms.
What is Medicinal Chemistry & Drug Development?
Medicinal chemistry is the branch of chemistry focused on the design and development of pharmaceutical compounds. In the context of psychedelics, this involves rigorous analysis of molecular structures, including how different substituents on phenethylamines can affect their psychoactive properties.
Key symptoms and effects of psychedelics generally include altered states of consciousness, changes in perception, emotional release, and potential therapeutic benefits in various mental health conditions. The exploration of these compounds is linked to their structural nuances and the chemical pathways they interact with in the human brain.
Current Treatments
Current treatment methodologies for mental health conditions often include selective serotonin reuptake inhibitors (SSRIs), psychotherapy, and other pharmacological interventions that aim to alleviate symptoms, though these are met with varying effectiveness across individuals.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Medicinal Chemistry & Drug Development.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD Clinical trials show robust evidence of LSD's efficacy in treating anxiety and depression. | Large | High | Consistent |
| Psilocybin Extensive studies support psilocybin's effectiveness in treating various psychological conditions. | Large | High | Consistent |
| MDMA Current research demonstrates significant benefits of MDMA-assisted therapy in PTSD patients. | Large | High | Consistent |
| Esketamine Esketamine shows promise as a rapid-onset treatment for severe depression. | Medium | Moderate | Consistent |
| Ayahuasca Empirical studies provide mixed results on its efficacy for mental health treatment. | Medium | Moderate | Inconsistent |
LSD and Medicinal Chemistry & Drug Development
LSD, or lysergic acid diethylamide, modulates serotonin receptors in the brain, leading to significant alterations in perception, cognition, and mood. These effects can facilitate therapeutic experiences, offering insights into personal trauma and emotional challenges that are often challenging to convey through conventional therapies.
Psilocybin and Medicinal Chemistry & Drug Development
Psilocybin, the active compound in magic mushrooms, shows promise in alleviating symptoms of depression and anxiety by impacting neural circuitry associated with emotional regulation. Recent studies suggest that psilocybin can induce lasting positive changes in mood and outlook, marking it as a potential catalyst for significant psychotherapeutic breakthroughs.
MDMA and Medicinal Chemistry & Drug Development
MDMA works primarily by increasing the release of serotonin, dopamine, and norepinephrine in the brain. This increase can lead to profound emotional insights and social bonding, which may assist individuals in confronting traumatic memories during therapy sessions, especially for PTSD patients seeking relief from acute psychological distress.
Clinical Outlook
The future of psychedelic treatment is poised for transformation as medicinal chemistry continues to unravel the intricacies of psychedelic molecules. With increasing regulatory approval and a push for bespoke psychedelic therapies, personalised medicine in mental health could become a reality by leveraging breakthroughs in chemistry.
Industrial Landscape
Key players include pharmaceutical companies, research universities, and non-profit organisations like MAPS and the Beckley Foundation, who are dedicated to advancing the science and safe utilisation of psychedelics.
Quick Indicators
Organisations
Search →Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
Delix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MycoMedica Life Sciences
MycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
University of Ottowa
The University of Ottawa launched a groundbreaking one-year MA in Psychedelics and Consciousness Studies in 2024, jointly offered by the Faculty of Social Sciences and Faculty of Arts under co-directors Dr. Monnica Williams and Dr. Anne Vallely. The program builds on earlier microprograms in Psychedelic Science and Psychedelics & Spirituality Studies established since 2020, training licensed professionals, clergy, and researchers in therapeutic, spiritual, and academic dimensions of psychedelics.
University of Auckland
The University of Auckland’s psychedelic therapy research programme centres on translating psychedelic science into clinically relevant mental health research. Led by Professor Suresh Muthukumaraswamy and colleagues, the programme has focused especially on LSD microdosing, with work examining effects on mood, cognition, brain function, and potential therapeutic use in conditions where current treatments remain inadequate. The university’s page frames this as a broader effort to explore psychedelic therapies for mental health, while university reporting shows the programme was seeded by philanthropic funding, later supported by the Health Research Council of New Zealand, and developed into a recognised research pathway within the institution. A key part of this work has involved microdosing trials conducted in collaboration with MindBio Therapeutics. University reporting states that MindBio provided commercial backing for the LSD microdosing research, including work that moved from healthy volunteer studies toward patient populations such as people with major depressive disorder. More recent Auckland-linked studies also show the programme expanding into other targeted applications, including late stage cancer care and menstrual health related questions, which suggests a research platform that is both mechanistic and clinically exploratory. In that sense, Auckland has become one of the more visible academic centres testing whether repeated low dose LSD can be developed into scalable, lower intensity psychedelic interventions.
Reconnect Labs
Reconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.
MindBio Therapeutics
MindBio Therapeutics is a clinical-stage biotechnology company developing MB22001, a proprietary titratable form of LSD designed for take-home microdosing. The company's Phase 2B trials in major depressive disorder and advanced-stage cancer distress have reported strong antidepressant effects, with Phase 2a data showing a 72% reduction in depressive symptoms and 58% remission at six months. MindBio is listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange.
King's College London
The Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
Helsinki University Central Hospital
Helsinki University Hospital (HUS) is Finland's largest academic medical center and the clinical partner of the University of Helsinki's Neuropsychopharmacology and Neuroscience Center laboratories, which produced the landmark discovery that psychedelics directly bind the TrkB BDNF receptor with far greater affinity than conventional antidepressants. As Finland's primary academic hospital, HUS provides the clinical infrastructure for ketamine-based treatments for suicidal depression and the planned translation of Finnish psychedelic neuroscience into human trials.
National Center for Complementary and Integrative Health (NCCIH)
U.S. federal institute focused on complementary/integrative research and evidence programs including psychedelic-adjacent contexts.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Connected Evidence
The latest clinical data and verified academic findings associated with Medicinal Chemistry & Drug Development.